Fennec Pharmaceuticals Inc.

NasdaqCM FENC

Fennec Pharmaceuticals Inc. Market Capitalization on January 14, 2025: USD 158.52 M

Fennec Pharmaceuticals Inc. Market Capitalization is USD 158.52 M on January 14, 2025, a -41.87% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

Fennec Pharmaceuticals Inc. 52-week high Market Capitalization is USD 299.05 M on March 28, 2024, which is 88.65% above the current Market Capitalization.
Fennec Pharmaceuticals Inc. 52-week low Market Capitalization is USD 109.45 M on November 15, 2024, which is -30.95% below the current Market Capitalization.
Fennec Pharmaceuticals Inc. average Market Capitalization for the last 52 weeks is USD 193.14 M.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

NasdaqCM: FENC

Fennec Pharmaceuticals Inc.

CEO	Mr. Rostislav Raykov
IPO Date	Sept. 15, 2017
Location	United States
Headquarters	68 TW Alexander Drive
Employees	29
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Key trends

Past 5 years